• AST 487: Evidence-Limited Product Overview

  2026-10-17

  APExBIO lists AST 487 under SKU A3194, but the available product page provides no identity details, mechanism, assay context, or matched research evidence. Accordingly, this overview distinguishes a commercial product listing from evidence about molecular action or biological performance.

• Nuclear cGAS and the CHK2–L1 Axis

  2026-10-16

  The cited Nature Communications study reported that nuclear cGAS restricted LINE-1 retrotransposition by promoting TRIM41-dependent degradation of ORF2p, with DNA-damage-responsive CHK2 phosphorylation strengthening this pathway. The findings provide a mechanistic framework for DNA damage response research, but they do not establish that the commercial compound BML-277 was used or that supplier-reported Chk2 inhibition reproduces the study’s effects.

• BML-277 and the CHK2–cGAS–L1 Axis

  2026-10-16

  The cited Nature Communications study supports a mechanistic model in which DNA-damage-responsive CHK2 phosphorylation enables nuclear cGAS to recruit TRIM41, promote ORF2p degradation, and restrain LINE-1 retrotransposition. This is evidence for a CHK2-dependent regulatory pathway, not proof that a particular commercial BML-277 formulation reproduces every reported phenotype. Supplier-reported biochemical potency and T-cell radioprotection remain separate measurement-context evidence with important applicability limits.

• EGFP-Targeting sgRNAs: Evidence and Scope

  2026-10-15

  The APExBIO listing identifies R2997 as three sgRNAs described as targeting EGFP in HeLa cells, with 3 μmol specified for each guide. That information supports a limited product-identity and mechanism overview, but no identity-matched paper, sequence record, performance result, comparator, or assay validation is available. The intended molecular logic is compatible with CRISPR-based targeting of an EGFP reporter, while any claim about editing, fluorescence loss, specificity, or reproducibility remains unsubstantiated for this product.

• CHK2–cGAS Control of LINE-1 Retrotransposition

  2026-10-15

  The supplied Nature Communications study supports a DNA-damage-responsive CHK2–cGAS–TRIM41 pathway that lowers LINE-1 ORF2p abundance and restricts retrotransposition. Its findings illuminate a noncanonical nuclear function of cGAS, but they do not establish that BML-277, a commercial Chk2 inhibitor described by APExBIO, was used or that its reported biochemical and T-cell effects reproduce this pathway.

• When Context Changes What MS-275 Means

  2026-10-14

  The same HDAC-inhibiting compound can signify different biological outcomes depending on model, tissue, timing, comparator, and readout. In axolotl limb regeneration, Wang et al. associated MS-275-sensitive HDAC activity with blastema formation and nerve-dependent HDAC1 expression, while broader product descriptions place Entinostat in oncology contexts where growth inhibition is the intended outcome.

• Probenecid: Evidence, Scope and Limitations

  2026-10-14

  Probenecid, also known as 4-(dipropylsulfamoyl)benzoic acid, is described by the supplier as a research compound affecting selected organic anion transporters, multidrug resistance-associated proteins and pannexin-1 channels. The supplied evidence supports a hypothesis-generating discussion of multidrug resistance reversal in leukemia and neuroprotection in cerebral ischemia/reperfusion injury, but it does not establish clinical efficacy, universal transporter selectivity or a validated therapeutic mechanism.

• Tofacitinib and RA Macrophage Comparisons

  2026-10-13

  A source-grounded interpretation of a 2026 comparison study examining Tofacitinib against cytokine- and metabolism-directed approaches in rheumatoid arthritis macrophage models, with emphasis on evidence strength, mechanistic uncertainty, and limits on clinical applicability.

• TAI-1: Evidence, Scope, and Limits

  2026-10-13

  TAI-1 is commercially described as a Hec1 inhibitor with a mitotic mechanism and preliminary anticancer activity. The supplied retinoblastoma organoid study provides important evidence about RB1-dependent retinal tumor initiation, but it does not test TAI-1 or establish that Hec1 inhibition is effective in retinoblastoma.

• Galectin-1, FIP200, and Hepatic Steatosis

  2026-10-12

  A 2026 study proposes that galectin-1 promotes hepatic steatosis and insulin resistance by binding the autophagy scaffold FIP200 and disrupting ULK-complex function. Its in vivo, proteomic, interaction-mapping, and mutation-based evidence supports a Gal-1–FIP200 mechanism in experimental models, but the supplied record does not establish relevance to human NAFLD or connect the pathway to Selonsertib, GS-4997, or ASK1 signaling.

• ATG4B, Energy Deficiency, and AML DNA Repair

  2026-10-12

  A 2025 Advanced Science study reports a mechanistic link between cellular energy deficiency, ATG4B nuclear translocation, impaired PRMT1–MRE11 DNA repair signaling, and acute myeloid leukemia progression. The findings are biologically informative but remain preclinical and do not establish clinical utility or a role for repaglinide.

• KR-12 and LL-37 Against MDR A. baumannii

  2026-10-10

  The 2013 reference study compared LL-37 with truncated fragments, including KR-12, across planktonic killing, adherence, biofilm, and cytotoxicity endpoints in multidrug-resistant Acinetobacter baumannii. Its main contribution was showing that LL-37-derived fragments can retain clinically relevant antibacterial and antibiofilm activity, while also revealing that activity against free-living cells does not automatically predict activity against established biofilms.

• Palmitic Acid (Hexadecanoic Acid): Product Overview

  2026-10-09

  Palmitic acid, also called hexadecanoic acid, is a supplier-listed saturated long-chain fatty acid identified as CAS 57-10-3, with formula C16H32O2 and molecular weight 256.42. No matched paper evidence is available here, so its research relevance is limited to the documented product description and stated conceptual scope.

• EdU Flow Cytometry in NSCLC DNA-Repair Research

  2026-10-09

  EdU-based flow cytometry offers a conceptual way to measure S-phase DNA synthesis while studying cancer cell-cycle responses. This overview places the EdU Flow Cytometry Assay Kits (Cy5) in the context of a recent NSCLC study linking CDK1, APE1, genome instability, p53-dependent invasion, and immune signaling. It distinguishes supplier claims from peer-reviewed evidence and outlines key interpretation limits.

• Flexible Phage Surfaces for Rare Cell Capture

  2026-10-08

  The reference study shows that mechanically flexible M13 bacteriophage nanofibers can improve circulating tumor cell capture while limiting nonspecific white blood cell adsorption. By combining target-cell enrichment with immunostaining, the authors reported strong discrimination between breast cancer patients and healthy donors and high accuracy for breast cancer subtype classification, while also identifying important boundaries for clinical interpretation.

8075 records 3/539 page Previous Next 12345 下5页 Last page